Oncolytics Biotech (ONC.TO, ONCY) on Friday said its fourth-quarter net loss doubled as the company advances towards registrational studies for its lead candidate pelareorep. A registration enabling trial is intended to generate sufficient data to file for a marketing application.
The net loss for the fourth quarter was $8.0 million, or $0.10 per share, compared with a loss of $3.9 million, or $0.05 per share, in the prior year period.
As at Dec. 31, Oncolytics reported $15.9 million in cash, giving it a projected cash runway through key milestones and into the third quarter of 2025.
Oncolytics is finalizing details for a large phase 2 study involving pelareorep in HR+/HER2- metastatic breast cancer, and expects a progression-free survival (PFS) readout two years after enrollment begins.
The final BRACELET-1 data showed robust improvements for patients receiving pelareorep and paclitaxel compared to paclitaxel monotherapy in terms of PFS, Oncolytics said. If a PFS benefit comparable to the results seen in BRACELET-1 is observed in the registration-enabling study, Oncolytics will file for accelerated approval with the Food and Drug Administration.
Oncolytics was last seen unchanged in New York trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。